Private Health Insurance (Prostheses) Rules 2013 (No. 1)

Administered by Department of Health, Disability and Ageing

Legislation au F2013L01576 Rules Not in force Legislative Instrument

Legislation content

EXPLANATORY STATEMENT

 

Issued by the Authority of the Minister for Health

Private Health Insurance Act 2007

Private Health Insurance (Prostheses) Rules 2013 (No. 1)

 

Section 333-20 of the Private Health Insurance Act 2007 (the Act) provides that the Minister may make Private Health Insurance (Prostheses) Rules, providing for matters required or permitted by Part 3-3 of the Act, or necessary or convenient in order to carry out or give effect to Part 3-3 of the Act.

 

The table in subsection 72-1(2) of Part 3-3 of the Act provides for requirements that a complying health insurance policy that covers hospital treatment must meet. Under item 4 of that table there must be a benefit for the provision of a prosthesis, of a kind listed in Private Health Insurance (Prostheses) Rules (i.e. a listed prosthesis), in specified circumstances and under any specified conditions. The specified circumstances are that the listed prosthesis is provided in circumstances in which a Medicare benefit is payable or in other circumstances which may be set out in Private Health Insurance (Prostheses) Rules. The specified conditions are any that may be set out in Private Health Insurance (Prostheses) Rules (currently there are two (2) specified conditions in relation to insulin infusion pumps, and in relation to prostheses with billing code SO041 (Osmed Sphere / Hemisphere tissue expander) and billing code CT016 (Restorelle M Smartmesh)). There are seven (7) specified conditions in relation to Ligament Augmentation & Reconstruction; That an Artificial Ligament should only be funded for intra-articular cases where no non-synthetic graft sources (allografts and autografts) are available. Billing Codes for Ligament Augmentation & Reconstruction are CR201 (Ligament Augmentation & Reconstruction System (LARS) AC30RA), CR202 (Ligament Augmentation & Reconstruction System (LARS) LAC 20), CR203 (Ligament Augmentation & Reconstruction System (LARS) LAC 30), CR204 (Ligament Augmentation & Reconstruction System (LARS) MCL 32), CR205 (Ligament Augmentation & Reconstruction System (LARS) - Rotator Cuff CR 25), CR206 (Ligament Augmentation & Reconstruction System (LARS) - Rotary Cuff CR 30), RQ070 (LIGASTIC reinforcement ligament).

 

If the complying health insurance policy also covers hospital-substitute treatment, under item of the table in subsection 72-1(2) of Part 3-3 of the Act the same requirements apply.

 

The purpose of the Private Health Insurance (Prostheses) Rules 2013 (No.1) (the Rules) is to list the kinds of prostheses in relation to the provision of which a benefit must be paid in the conditions and circumstances specified, and set out the minimum and, where applicable, maximum benefit payable.

 

The Rules revoke the Private Health Insurance (Prostheses) Rules 2012 (No. 2) (the Previous Rules).

 

The Schedule to the Rules has three parts:

  • Part A – Prostheses List;
  • Part B – Human Tissue List; and
  • Part C – Other Prostheses.

 

The Rules differ from the Previous Rules by:

  • making technical amendments, including:

         amending the reference to general medical services table in the definition of ‘professional attendance’ in rule 4 for consistency with the Health Insurance Act 1973;

         moving note 2 to rule 8 to the appropriate position;

         including numbering in the notes to rule 10 for clarity;

  • adding 513 new items to Part A of the Schedule as no gap prostheses or gap permitted prostheses;
  • changing the current listing of many existing products in Parts A and B of the Schedule including:

        amending the descriptions of products;

        allocating new billing codes in respect of expansions of existing billing codes;

        compressing billing codes to cover a range of products offered at the same benefit;

        changing sponsor names to reflect new sponsor arrangements; and

        changing the minimum benefit and/or maximum benefit;

        removing products from Part A of the schedule.

 

In Part A of the Schedule, products are grouped according to their clinical effectiveness, as assessed by Clinical Advisory Groups (CAGs) or the Panel of Clinical Experts (PoCE).  The purpose of the groupings is to identify products of similar clinical effectiveness or clinical design, in order to assist in determining the benefits payable for the products and to assist with clinical choice.

 

Benefits payable for new products have been developed either as part of the implementation of recommendation 12 b-e of the Health Technology Assessment (HTA) Review or by the Department. Implementation of the HTA Review recommendation involved the refinement of grouping schemes and the development of group benefits for clinically similar products, which was guided by the Health Technology Assessment Review Consultative Committee and endorsed by the PLAC (Prostheses List Advisory Committee).  Development of benefits by the Department used a similar process and was endorsed by the PLAC.  

 

CONSULTATION

 

The Rules have been made having regard to recommendations made by the Prostheses List Advisory Committee (PLAC), which is a ministerially appointed committee comprised of members from health insurers, hospitals, clinicians, prostheses sponsors and consumer representatives. 

 

In making its recommendations, the PLAC was advised by CAGs, other clinical experts, and the Health Technology Assessment Review Consultative Committee.

 

Details of the Rules are set out in the Attachment.

 

The Rules commence on 31 August 2013.

 

The Rules are a legislative instrument for the purposes of the Legislative Instruments Act 2003.

 

 

Authority:  Section 333-20 of the

           Private Health Insurance

Act 2007

 

 


ATTACHMENT

 

DETAILS OF THE PRIVATE HEALTH INSURANCE (PROSTHESES) RULES 2013 (No.  1)

 

PART 1  PRELIMINARY

 

1.  Name of Rules

 

Rule 1 provides that the title of the Rules is the Private Health Insurance (Prostheses) Rules 2013 (No.  1).

 

2.  Commencement and authority

 

Rule 2 provides for the Rules to commence on 31 August 2013 and that the Rules are made under item 4 of the table in section 333-20 of the Private Health Insurance Act 2007 (the Act).

 

3. Revocation

 

Rule 3 provides for the revocation of the Private Health Insurance (Prostheses) Rules 2012 (No.2).

 

4.  Definitions

 

Terms used in the Rules have the same meaning as in the Act. In addition, certain terms are defined for the purposes of the Rules, including the definitions of gap permitted prosthesis and no gap prosthesis. 

 

Part 2  Benefit requirements

 

5.  Listing of, and benefits for, prostheses

 

The table in subsection 72-1(2) of the Act (the Table) sets out some requirements that a policy that covers hospital treatment must meet in order for the policy to be a complying health insurance policy under section 63-10 of the Act. Item 4 of the Table provides that there must be a benefit for hospital treatment covered under the policy (and hospital substitute treatment, where the policy also covers such treatment) that is the provision of a listed prosthesis both:

  • in the circumstances in which a medicare benefit is payable or those other circumstances set out in the Private Health Insurance (Prostheses) Rules; and
  • when the conditions set out in the Private Health Insurance (Prostheses) Rules (if any) are also satisfied. If the conditions are not satisfied, there is no benefit required even if the listed prosthesis is provided in the circumstances set out either under the Act or the Private Health Insurance (Prostheses) Rules. 

 


Paragraph 5(a) provides that the Schedule to the Rules sets out listed prostheses.  The listed prostheses are:

  • kinds of prostheses in relation to which the Minister has granted an application for listing under subsection 72-10(5) of the Act, including those for which the applicant has paid any initial listing fee imposed under the Private Health Insurance (Prostheses Application and Listing Fees) Act 2007 within the specified timeframe; and
  • kinds of prostheses that were, immediately before the commencement of the Act on 1 April 2007, listed as a no gap prosthesis or a gap permitted prosthesis for the purposes of the National Health Act 1953 (see section 12, Private Health Insurance (Transitional Provisions and Consequential Amendments) Act 2007).

 

Paragraph 5(aa) provides that the circumstances in which there must be a benefit payable for the provision of a listed prosthesis, other than circumstances in which a medicare benefit is payable, are set out in rule 5A of the Rules. 

 

Paragraph 5(ab) provides that conditions that must be satisfied in relation to the provision of a listed prosthesis in order for a benefit to be payable are set out in rule 5B of the Rules.  These conditions further limit when a benefit is required to be payable for the provision of a listed prosthesis in the circumstances where a medicare benefit is payable (refer to paragraph (c), item 4 of the Table) or in the circumstances which are set out in the Rules (refer to paragraph (d), item 4 of the Table). 

 

Paragraph 5(b) provides that rule 6 sets out the method for working out the minimum and maximum benefit for hospital treatment, covered under a complying health insurance policy, that is the provision of a listed prosthesis.

 

Paragraph 5(c) provides that rule 7 sets out the method for working out the minimum benefit and maximum benefit for hospital-substitute treatment, covered under a complying private health insurance policy, that is the provision of a listed prosthesis.

 

It is not possible for a private health insurer to cover hospital treatment or hospital-substitute treatment under a policy, but exclude coverage of the provision of an associated listed prosthesis. This coverage requirement is provided for in Rule 8 of the Private Health Insurance (Complying Product) Rules.

 

5A. Circumstances in which a prosthesis is provided other than circumstances in which a medicare benefit is payable

 

Rule 5A specifies circumstances for the purposes of paragraph (d) of item 4 of the Table. A benefit must be payable under a policy which is a complying health insurance policy for covered hospital treatment and hospital-substitute treatment (if the policy covers hospital-substitute treatment) that is the provision of a listed prosthesis which is associated with podiatric treatment by an accredited podiatrist. This is the case even if a medicare benefit is not payable for that provision.

 

A note to rule 5A provides that the provision of a listed prosthesis in circumstances in which a medicare benefit is payable is dealt with in paragraph (c) of item 4 of the Table.

 


5B. Conditions in relation to provision of a listed prostheses

 

Under paragraphs (c) and (d) of item 4 in the Table, the Private Health Insurance (Prostheses) Rules may set out conditions that must be satisfied in relation to the provision of a listed prosthesis in circumstances in which a medicare benefit is payable, or in the circumstances set out in rule 5A, whatever the case may be. If these conditions are not satisfied, no benefit is required to be payable under a complying health insurance policy that covers hospital treatment. 

 

Rule 5B specifies that the conditions that must be satisfied are:

 

  • in the case of any listed prosthesis for which there is a statement of a requirement under the heading ‘Condition’ in the Schedule under the listing for that kind of prosthesis, that requirement (paragraph 5B(a)).There are nine (9) prostheses in the Schedule which have a condition and they are SO041 (Osmed Sphere / Hemisphere tissue expander), CT016 (Restorelle M Smartmesh), CR201 (Ligament Augmentation & Reconstruction System (LARS) AC30RA), CR202 (Ligament Augmentation & Reconstruction System (LARS) LAC 20), CR203 (Ligament Augmentation & Reconstruction System (LARS) LAC 30), CR204 (Ligament Augmentation & Reconstruction System (LARS) MCL 32), CR205 (Ligament Augmentation & Reconstruction System (LARS) - Rotator Cuff CR 25), CR206 (Ligament Augmentation & Reconstruction System (LARS) - Rotary Cuff CR 30), RQ070 (LIGASTIC reinforcement ligament); and
  • in the case of a listed prosthesis that is an insulin infusion pump, in addition to any statement of requirement which is set out in the Schedule: the professional service associated with providing the insulin infusion pump to the patient is a professional attendance by a consultant physician in the practice of his or her specialty; and is provided as a certified Type C or certified overnight Type C procedure.  The insulin infusion pump must also be provided for the purpose of administering insulin. 
  • That an Artificial Ligament should only be funded for intra-articular cases where no non-synthetic graft sources (allografts and autografts) are available.

 

6.  Benefits for prostheses provided as part of hospital treatment

 

Subrule 6(1) provides that, for a no gap prosthesis provided as part of an episode of hospital treatment by a private hospital, the minimum and maximum benefit are each the amount for that prosthesis set out under the column heading ‘Minimum Benefit’ in the Schedule.

 

Subrule 6(2) provides that, for a gap permitted prosthesis provided as part of an episode of hospital treatment by a private hospital, the minimum benefit and the maximum benefit are the amounts set out in the Schedule for that prosthesis under the column headings ‘Minimum Benefit’ and ‘Maximum Benefit’.

 

Subrule 6(3) provides that, for a no gap prosthesis provided as part of an episode of hospital treatment by a public hospital, the minimum benefit is the lesser of:

  • the amount for that prosthesis set out in the Schedule under the column heading ‘Minimum Benefit’; or
  • the amount of the insured person’s liability to the public hospital for that prosthesis.

The maximum benefit is the amount for that prosthesis set out under the column heading ‘Minimum Benefit’ in the Schedule.

 

Subrule 6(4) provides that, for a gap permitted prosthesis provided as part of an episode of hospital treatment by a public hospital, the minimum benefit is the lesser of:

  • the amount for that prosthesis set out in the Schedule under the column heading ‘Minimum Benefit’; or
  • the amount of the insured person’s liability to the public hospital for that prosthesis.

The maximum benefit is the amount for that prosthesis set out under the column heading ‘Maximum Benefit’ in the Schedule.

 

7.  Benefits for prostheses provided as part of hospital-substitute treatment

 

Subrule 7(1) provides that, for a no gap prosthesis provided as part of an episode of hospital substitute treatment, the minimum and maximum benefit are each the amount for that prosthesis set out under the column heading ‘Minimum Benefit’ in the Schedule.

 

Subrule 7(2) provides that, for a gap permitted prosthesis provided as part of an episode of hospital-substitute treatment, the minimum benefit and the maximum benefit are the amounts set out in the Schedule for that prosthesis under the column headings ‘Minimum Benefit’ and ‘Maximum Benefit’.

 

 

8.  Timing of applications

 

Rule 8 provides that, as a matter of normal administrative practice, if the Minister grants an application, then the prosthesis must be listed in the Schedule the next time the Minister makes or varies the rules.

 

 

9.  Minister may have regard to recommendations and advice

 

Rule 9 provides that, in making a decision under section 72-10 of the Act, the Minister may have regard to a recommendation from the Prostheses List Advisory Committee when deciding whether or not to grant the application to list a prosthesis.

 

 

10.  Listing criteria for prostheses to be listed in Part C of the Schedule

 

Rule 10 sets out the listing criterion that must be met for a listing application to be granted for listing a kind of prosthesis in Part C of the Schedule. This criterion is that the kind of prosthesis is either an insulin infusion pump or an implantable cardiac event recorder.

 

Notes to rule 10 provide that:

  •         the power to make listing criteria is found in subsection 72-10(6) of the Act; and
  •         the Minister may not grant a listing application if any applicable listing criteria have not been met, and the Minister has the power to refuse to grant a listing application even if the listing criteria have been satisfied (see subsection 72-10(7) of the Act).

 

 


SCHEDULE

 

The Schedule lists kinds of prostheses and contains the ‘Minimum Benefit’ and ‘Maximum Benefit’ for kinds of prostheses for private and public hospital treatment, and hospital-substitute treatment.

 


Statement of Compatibility with Human Rights

Prepared in accordance with Part 3 of the Human Rights (Parliamentary Scrutiny) Act 2011

 

Private Health Insurance (Prostheses) Rules 2013 (No. 1)

 

This Legislative Instrument is compatible with the human rights and freedoms recognised or declared in the international instruments listed in section 3 of the Human Rights (Parliamentary Scrutiny) Act 2011.

 

Overview of the Legislative Instrument

The Private Health Insurance (Prostheses) Rules 2013 (No. 1) (the Rules): (a) revoke the Private Health Insurance (Prostheses) Rules 2012 (No. 2) (the Previous Rules); and (b) list the kinds of prostheses in relation to the provision of which a benefit must be paid in the conditions and circumstances specified, and set out the minimum and, where applicable, maximum benefit payable.

 

Changes to the Previous Rules include:

 

  • adding 513 new items to the prostheses list as no gap prostheses or gap permitted prostheses;
  • changing the current listing of many existing products in the prostheses list and human tissue list including:

         amending the descriptions of products;

         allocating new billing codes in respect of expansions of existing billing codes;

         compressing billing codes to cover a range of products offered at the same benefit;

         changing sponsor names to reflect new sponsor arrangements; and

         changing the minimum benefit and/or maximum benefit;

  • deleting 679 products in the prostheses list.


Human rights implications

The Rules engage the following human rights:

 

Right to Health

 

The right to health – the right to the enjoyment of the highest attainable standard of physical and mental health – is contained in article 12(1) of the International Covenant on Economic Social and Cultural Rights (ICESCR).  Whilst the UN Committee on Economic Social and Cultural Rights (the Committee) has stated that the right to health is not to be understood as a right to be healthy, it does entail a right to a system of health protection which provides equality of opportunity for people to enjoy the highest attainable level of health.

 

The addition of 513 items to the Schedule of the Rules as no gap prostheses or gap permitted prostheses will ensure that an insured person with appropriate cover will receive a minimum benefit for the provision of the prosthesis as hospital treatment or, where applicable hospital-substitute treatment, and:

  • the prosthesis is provided in circumstances where a Medicare benefit is payable and any relevant conditions in the Rules are met; or
  • the prosthesis is provided in other circumstances specified in the Rules and any relevant conditions are met.

 

The addition of new items will increase the amount of choice an insured person can have in relation to the type of prostheses for which they must receive a minimum benefit.  This will impact positively on the right to health of insured persons.

 

The Rules also remove entries for 351 prostheses at the request of the sponsors of these prostheses. The sponsors of these prostheses are no longer supplying these prostheses for use to privately insured persons in Australia.

 

Generally the prostheses removed from the Rules have been replaced by newer models due to upgraded technologies or advancements in surgical procedures. 

 

Conclusion

The Rules are compatible with human rights because they advance the protection of human rights.

Richard Bartlett

First Assistant Secretary

Medical Benefits Division

Department of Health and Ageing

 

Interactions

Authorises

All Versions

Sourced from the Federal Register of Legislation at 26 August 2026. For the latest information on Australian Government law please go to https://www.legislation.gov.au.